scholarly journals Nasal mucosal dysplasia induced by topical corticosteroids with benzalkonium chloride

2018 ◽  
Vol 9 (2) ◽  
pp. 126 ◽  
Author(s):  
Funda Tamer ◽  
Erol Koc ◽  
Taylan Gun ◽  
Can Ergin
Keyword(s):  
Benzalkonium Chloride ◽  
Topical Corticosteroids ◽  
Mucosal Dysplasia

Studies on Adrenocortical Suppression Following Percutaneous Absorption of Topical Corticosteroids

1973 ◽  
Vol 35 (4) ◽  
pp. 472-476 ◽  
Author(s):  
Shuhei SHIMAO ◽  
Yasuyuki SHIMIZU ◽  
Motoyuki MIHARA ◽  
Toshiaki USUI ◽  
Hiroko KAWAMOTO
Keyword(s):  
Percutaneous Absorption ◽  
Topical Corticosteroids

Benzalkonium chloride interferes with energy production, secretion and morphology in human blood platelets

Platelets ◽  
1999 ◽  
Vol 10 (2) ◽  
pp. 97-104 ◽  
Author(s):  
Ø. Berg ◽  
A. M. Bakken ◽  
S. K. Steinsvåg ◽  
M. Farstad
Keyword(s):  
Human Blood ◽  
Benzalkonium Chloride ◽  
Energy Production ◽  
Blood Platelets ◽  
Human Blood Platelets

Vitiligo: An Updated Narrative Review

2020 ◽  
Vol 16 ◽  
Author(s):  
Alexander K. C. Leung ◽  
Joseph M. Lam ◽  
Kin Fon Leong ◽  
Kam Lun Hon
Keyword(s):  
Present Article ◽  
English Literature ◽  
Disease Onset ◽  
Clinical Manifestations ◽  
Calcineurin Inhibitors ◽  
Ultraviolet B ◽  
Lower Limbs ◽  
Treatment Modalities ◽  
Topical Corticosteroids ◽  
Topical Calcineurin Inhibitors

Background: Vitiligo is a relatively common acquired pigmentation disorder that can cause significant psychological stress and stigmatism. Objective: This article aims to familiarize physicians with the clinical manifestations, evaluation, diagnosis, and management of vitiligo. Methods: A Pubmed search was conducted in Clinical Queries using the key term "vitiligo". The search included metaanalyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to the English literature. The information retrieved from the above search was used in the compilation of the present article. The information retrieved from the above search was used in the compilation of the present article. Results: Approximately one quarter of patients with vitiligo have the onset before 10 years of age. Genetic, immunological, neurogenic and environmental factors may have a role to play in the pathogenesis. Vitiligo typically presents as acquired depigmented, well-demarcated macules/patches that appear milk- or chalk-white in color. Lesions tend to increase in number and enlarge centrifugally in size with time. Sites of predilection include the face, followed by the neck, lower limbs, trunk, and upper limbs. The clinical course is generally unpredictable. In children with fair skin, no active treatment is usually necessary other than the use of sunscreens and camouflage cosmetics. If treatment is preferred for cosmesis, topical corticosteroids, topical calcineurin inhibitors, and narrowband ultraviolet B phototherapy are the mainstays of treatment. Conclusion: The therapeutic effect of all the treatment modalities varies considerably from individual to individual. As such, treatment must be individualized. In general, the best treatment response is seen in younger patients, recent disease onset, darker skin types, and head and neck lesions. Topical corticosteroids and calcineurin inhibitors are the treatment of choice for those with localized disease. Topical calcineurin inhibitors are generally preferred for lesions on genitalia, intertriginous areas, face, and neck. Narrowband ultraviolet B phototherapy should be considered in patients who have widespread vitiligo or those with localized vitiligo associated with a significant impact on the quality of life who do not respond to treatment with topical corticosteroids and calcineurin inhibitors.

Sign in / Sign up

Export Citation Format

Share Document